Laquinimod

Drug Profile

Laquinimod

Alternative Names: ABR-215062; Laquinimod sodium; Nerventra; SAIK-MS; TV-5600

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Active Biotech
  • Developer Icahn School of Medicine at Mount Sinai; National University of Singapore; Ruhr-University Bochum; Tel Aviv University; Teva Pharmaceutical Industries; University College London; University of British Columbia
  • Class Quinolones; Small molecules
  • Mechanism of Action Brain-derived neurotrophic factor expression stimulants; Immunomodulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Multiple sclerosis
  • Phase II Crohn's disease; Huntington's disease
  • No development reported Lupus nephritis
  • Discontinued Systemic lupus erythematosus

Most Recent Events

  • 16 Feb 2017 Laquinimod receives Orphan Drug status for Huntington's disease in USA before February 2017
  • 19 Sep 2016 The USFDA rescinds the Special Protocol Assessment for the phase III CONCERTO trial
  • 07 Oct 2015 Interim pharmacodynamics data from preclinical trials in Multiple sclerosis released by Teva
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top